Remove 2003 Remove Biopharma Remove Leads Remove Patients
article thumbnail

FINN Partners Further Expands into Asia with Addition of SPAG

PM360

FINN Partners , an independent marketing and communications agency, is expanding its global footprint even further with the addition of SPAG , a leading, Asia-headquartered, health-sector communications and marketing firm with offices in Bangalore, Delhi, Indonesia, Malaysia, Mumbai, the Philippines, and Singapore. and Europe.

article thumbnail

How VMS BioMarketing Accelerated Digital Transformation with Silverline

Silver Line CRM

Reading time: 4 minutes A patient support network isn’t made up of just doctors or nurses. Through contracting with pharmaceutical and biotech companies, VMS BioMarketing provides clinical educator solutions focused on empowering healthcare providers and patients through product support, education, and training.

Insiders

Sign Up for our Newsletter

This site is protected by reCAPTCHA and the Google Privacy Policy and Terms of Service apply.

Trending Sources

article thumbnail

Targeting tumours with novel radiopharmaceuticals

European Pharmaceutical Review

billion deal, in which Eli Lilly agreed to acquire two of POINT Biopharma Global’s late-stage radioligand therapies for oncological indications. These diagnostics have significantly progressed based on rigorous Phase III trial designs and because of the impact these diagnostics have had on patient management.

article thumbnail

The Biotech Effect

Pharmaceutical Technology

“The inherent advantages of biopharma are that it allows you to pursue therapies against targets that are not small molecule therapies, for example by targeting protein-protein interactions and targeting GPCRs (G-protein coupled receptors),” he says. “Biotechnology has exploded across the industry. .”

article thumbnail

Building CO2-neutral, defossilised supply chains for chemicals

European Pharmaceutical Review

Production and value creation can be regionalised and decentralised, which could lead to a more resilient economic structure. During his time at Genentech Stefan has advanced several small molecules and new modalities (antibody‑drug conjugates, oligonucleotides and peptides) into the clinic as lead chemist and technical development leader.